Login / Register The Most Trusted Name in Medical Education

Primary Care

Elsevier's Office of Continuing Medical Education offers the most comprehensive list of primary care CME courses. Check out the list below to ramp up on the latest topics in primary care.

910730 LC 116 x 140

Clinical Advances in Chronic Obstructive Pulmonary Disease: A Focus on Improving Patient Outcomes Learning Center

Format: Resource Center

Welcome to Clinical Advances in Chronic Obstructive Pulmonary Disease: A Focus on Improving Patient Outcomes Learning Center. The Learning Center provides you with free access to the latest clinical information relating to the diagnosis and management of COPD. The COPD Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational (CME) activities, research articles and resources for healthcare providers who treat patients with COPD.

Go to Learning Center »

910748 116 x 140

THE ROLE OF PCSK9 INHIBITORS IN LOWERING LDL-C AND REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH DYSLIPIDEMIA

Format: Conference Reporter

This CME program will feature content presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain. Four expert faculty will analyze recent therapeutic advances in the treatment and management of patients with dylispidemia, as well as the role of PCSK9 inhibitors in lowering LDL-C and reducing cardiovascular risk in those patients. Long-term cardiovascular efficacy and safety data will be reviewed, and clinical relevance debated. Further, the expert faculty will outline strategies for utilizing the inter-professional team and incorporating recent data into individualized treatment plans. Upon completion of this CME activity, learners will have a better grasp of evolving science in the field of dyslipidemia as it relates to improving outcomes and quality of life in clinical practice.

 

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
116x140 RGNRN ATS ASTHMA2

CLINICAL ISSUES IN SEVERE ASTHMA: CONSENSUS AND CONTROVERSIES ON THE ROAD TO PRECISION MEDICINE

Format: Webcast

This CME-accredited Clinical IssuesTM program is intended for allergists/clinical immunologists, pulmonologists, and other healthcare providers involved in the management of patients with severe asthma. During the activity, a panel of expert faculty discuss and debate a series of topics related to the evaluation and long-term treatment of various severe asthma phenotypes. Activity topics include classification of severe asthma, disease biomarkers, comorbidity management, and current and emerging targeted biologic therapies. The goal is to provide clinician learners with the latest evidence and a fresh perspective on evolving management paradigms for severe asthma.

 

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910701 116 x 144

Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care

Format: Webcast Series

This CME-accredited CME Snapshot™ educational series, Breathing Life Into COPD Management: Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care is intended for primary care clinicians and other health care providers involved in the ongoing management of patients with chronic obstructive pulmonary disease (COPD). Within each focused activity, an expert pulmonologist and a primary care educator discuss best practices for a specific aspect of managing patients with COPD, including monitoring the disease course over time, maximizing patient function, and individualizing treatment regimens. One activity also addresses patients’ perspectives by incorporating patient-clinician interactions and insights into disease burdens, challenges to good long-term outcomes, and shared decision-making. 

Take Course »

 

Credits: 0.25 AMA PRA Category 1 Credit™
910742 116 x 140

The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients With Cystic Fibrosis

Format: Live Meeting

This live, inter professional continuing education seminar will highlight the latest advances in CFTR-based therapeutics for the treatment of patients with cystic fibrosis. The expert faculty will utilize an interactive panel format to present and discuss recent trial data as it relates to clinical decision-making, including updates regarding the assessment, monitoring, and management of patients treated with CFTR modulated therapies. This educational activity is intended to increase the knowledge and competencies of the multidisciplinary team involved in the care of the CF patient population. Upon completion of this educational activity, the healthcare team will be better equipped with vital information for improving outcomes and quality of life in patients with cystic fibrosis.

 

Take Course »

 

Credits: 1.75 AMA PRA Category 1 Credit(s)™ and 1.75 Nursing Contact Hours
910734 116 x 140

CYSTIC FIBROSIS INTERVIEW WEBCAST SERIES

Format: Webcast

This activity includes eight 30-minute modules that bring learners up to date on all aspects of cystic fibrosis (CF) treatment and management. Dr. John P. Clancy interviews eight experts in the CF field, each with their own specialization. The individual modules will focus on different areas of CF care, ranging from newborn screening to long-term real world efficacy and safety data. Each module is worth approximately 0.5 CME/CNE credits.

 

Take Course »

 

Credits: 8 Modules Total - Approx. 0.5 AMA PRA Category 1 Credit™ / CNE Credits Each
Thumbnail

How Immune Checkpoint Inhibitors Are Changing the Treatment Landscape for Metastatic Melanoma

Format: Live Meeting

Metastatic melanoma has a high mortality rate and is refractory to traditional treatments but recent clinical trials have shown significantly improved patient outcomes with checkpoint inhibitors. However, treating physicians may find its use challenging due to limited clinical experience and confidence in prescribing immunotherapies, especially among patient populations under-represented in clinical trials and in managing immune-related adverse events. This satellite symposium will cover the current practices and challenges in management of metastatic melanoma, as well as insights on the future management of melanoma patients.

Take Course >>

Credits: 1.0 AMA PRA Category 1 Credit(s)™
910735 updates 116 x 140

An Update on Scientific Advances and Clinical Strategies in Migraine

Format: Conference Reporter

The 59th Annual Scientific Meeting of the American Headache Society (AHS) was held in Boston, Massachusetts, June 8 to June 11, 2017. The conference attracts medical professionals involved in the care of patients with head, neck, and orofacial pain. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on migraine. 

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit(s)™
Elsevier ASHG 2017 10 Web 116x140 v1 thumbnail

Spotlight on the Critical Issues in the Treatment of Fabry Disease

Format: Live Meeting

During this symposium, we will provide an overview of the clinical picture of Fabry disease and its natural history. We will continue with guidance for identifying the correlation between genotype and phenotype and the ways it may affect disease progression. To finish we will discuss the current need for individualized patient care and review the emerging treatment landscape via the latest scientific data. Using interactive plenary sessions and selected patient case presentations, our expert panel will encourage the exchange of views and opinions on diagnosing and treating this disease.

Register Here >>

Credits: 1.5 AMA PRA Category 1 Credit(s)™
910703 116 x 140

Current and Future Therapies for Cytomegalovirus (CMV) Infection

Format: Webcast

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT, as well as with increased risk of secondary bacterial and fungal infections. Antiviral prophylaxis, more commonly used after SOT, is effective against direct and indirect effects of CMV infection, but may lead to overtreatment. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Several antiviral agents are currently available for CMV management; however, their use may be associated with myelosuppression and nephrotoxicity. Novel antiviral therapies with different mechanisms of action are in late-stage development and hold the promise of reducing CMV-related morbidity and mortality.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit(s)™
2017 13 116x140

Irritable Bowel Syndrome: Latest Advances in Pathophysiology, Diagnosis, and Patient Management

Format: Webcast

Inflammatory bowel syndrome (IBS) is the most common gastrointestinal disorder seen by primary care providers, yet it remains a source of frustration for both patients and physicians. Recent advances in our understanding of the etiology and pathophysiology of IBS have led to new diagnostic guidelines that avoid unnecessary testing so that IBS is no longer a diagnosis of exclusion. Treatment options are varied and evolving and include pharmacologic and non-pharmacologic options depending on the subtype of IBS and individual patient characteristics. This archived symposium will provide participants with the opportunity to assess new data and remaining challenges in the diagnosis and treatment of patients with IBS via interactive case scenarios.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910714 116 x 140

Focus on Uterine Fibroids: Evolving Options to Optimize Care

Format: Webcast

The content for this activity is based on the CME Forum Focus on Uterine Fibroids: Evolving Options to Optimize Care that was presented at the 2017 ACOG Annual Clinical and Scientific Meeting in San Diego, California, on May 8, 2017.

Register Now»

Credits: 1.00 AMA PRA Category 1 Credit(s)™
AAN 116 x 140

Applying New Science to Improve Outcomes for Patients with Multiple Sclerosis

Format: Conference Reporter

 This CME program will feature content presented at the the 69th Annual American Academy of Neurology (AAN) Meeting held in Boston, Massachusetts. Three expert faculty will analyze recent therapeutic advances in the treatment and management of patients with multiple sclerosis. The clinical relevance of emerging and emerged trial data will be reviewed. Faculty will discuss strategies for utilizing the multidisciplinary team approach to develop and implement personalized treatment plans, accommodating patient-specific disease characteristics. Upon completion of the activity, learners will have a better grasp of evolving science in the field of multiple sclerosis as it relates to clinical practice.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910702 E 116 x 140

Developing Optimized Treatment Plans for Patients with Dyslipidemia in the Era of PCSK9 Inhibitor Therapeutics

Format: Webcast

This educational content was derived from the American College of Physicians (ACP) Internal Medicine Meeting 2017 in San Diego, California. This activity will focus on optimized treatment plans for patients with dyslipidemia in the era of PCSK9 inhibitor therapeutics. LDL-C has been identified as an important therapeutic target to prevent the progression of atherosclerotic disease, however only 1 out of every 3 adults with high LDL-C has the condition under control. Expert faculty on this panel will discuss the science of PCSK9 inhibitors and aid physicians in the best practices to get their patients at LDL-C target.

Take Course »

Credits: 2.00 AMA PRA Category 1 Credit(s)™
2017 19 116x140

Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic Dermatitis

Format: Webcast

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research on AD presented at the American Academy of Dermatology 2017 Annual Meeting.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910687 116x140

Severe Asthma and the Primary Care Provider: Identifying Patients and Coordinating Multidisciplinary Care

Format: Webcast

This CME-accredited Through Your Patient’s EyesTM program is intended for primary care providers and other clinicians who manage patients with asthma. This educational activity has been designed to highlight issues faced by people living with asthma, including patients’ perspectives on the burdens of severe disease, difficulties related to suboptimal health literacy, and potential hurdles that can arise in busy healthcare practices. Specialist and primary care faculty discuss practical advice on overcoming these challenges, how to best coordinate multidisciplinary care, and actionable recommendations on identifying, comprehensively assessing, and longitudinally managing patients with severe asthma. As a result, clinician learners will be better prepared to engage and educate their patients with severe asthma, while improving long-term outcomes through personalized evidence-based care.  

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™ or 1.00 Nursing Contact Hours
910654 116 x 140

Updates in Improving Care of Patients With Rheumatoid Arthritis

Format: Interactive Monograph

Rheumatoid arthritis (RA) remains a clinically-challenging autoimmune disorder for rheumatologists to manage. Effective patient care is critical: an estimated sixty percent of people with inadequately-treated RA are unable to work 10 years following onset of the disease. The American College of Rheumatology (ACR) has endorsed the use of several quality improvement measures in RA management, including recommended screening, disease activity assessment, and treatment guidelines. However, clinical care of patients with respect to guideline recommendations continue to be suboptimal. 

Take Course »

Credits: 1.75 AMA PRA Category 1 Credit(s)™
138 17 287 JS 140x117

Immunotherapy: The Wave of the Future in Bladder Cancer?

Format: Supplement

This article reviews the role of immunotherapy in the treatment of locally advanced and metastatic urothelial cell carcinoma (UC). It describes the basic principles of cancer immunotherapy, as they relate to management of UC, and summarizes clinical data on current and investigational therapeutic approaches. Two immune checkpoint inhibitors are now approved for treatment of advanced UC in the United States, and the article discusses their unique response patterns and side effect profiles to help oncology clinicians appropriately incorporate these agents into patient care.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910728 116 x 140

An Update on Scientific Advances and Clinical Strategies in Chronic Obstructive Pulmonary Disease (COPD) from the ATS 2017 International Conference

Format: Conference Reporter

The 2017 American Thoracic Society (ATS) International Conference was held in Washington, DC, May 19–24, 2017. As a leading meeting in respiratory medicine, dedicated to advancing the clinical and scientific understanding of pulmonary diseases, critical illnesses, and sleep-related breathing disorders, the ATS Conference attracts thousands of participants from around the world. The 2017 ATS conference featured 6700 original research projects, 500 sessions, and 800 speakers. In this activity, 2 experts summarize the key learnings on COPD from this year’s conference.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910688 116x140

Caring for Patients with Severe Asthma: Evolving Best Practices to Optimize Outcomes

Format: Webcast

This CME-accredited Clinical Research UpdatesTM program is intended for allergists/clinical immunologists, pulmonologists, and other healthcare providers involved in the identification, evaluation, and treatment of patients with severe asthma. During the activity, a panel of expert faculty discuss and debate the latest evidence for severe asthma phenotypes, the clinical utility of various disease biomarkers, and the profiles of current and emerging biologic therapies, with a focus on individualizing treatment plans. Faculty also incorporate the perspectives of patients with asthma, including the burdens of severe disease, hidden challenges to good long-term outcomes, and the benefits of shared decision-making. 

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910647e 116 x 140

Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment

Format: Webcast

The content for this activity is based on the satellite symposium Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment that was presented on October 24, 2016 in Los Angeles, CA. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrotic lung disease of unknown cause. Early diagnosis is a prerequisite for earlier treatment and, potentially, improved long-term clinical outcomes. Familiarity with novel treatment approaches that hold the promise of slowing disease progression and with the recent guideline recommendations is essential for all clinicians involved in the care of patients with IPF. Individualizing treatment is important in light of potential improved adherence to both drug therapy and health behaviors. 

Register »

 

Credits: 1.25 AMA PRA Category 1 Credit(s)™
910655 116 x 140

Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic Fibrosis

Format: Webcast

The content for this activity is based on the satellite symposium, “Applying Recent Advances in the Science of CFTR-based Therapeutics to Improve Outcomes in Patients With Cystic Fibrosis”, that was presented at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida on October 28, 2016. The content highlights the latest advancements, particularly in CFTR-based therapeutics, for the treatment of patients with cystic fibrosis. Expert faculty discuss the most up-to-date analysis for clinical decision-making, including updates on assessment, monitoring, and management of patients treated with CFTR modulator therapies. The goal of this activity is to increase the knowledge and competencies of the multidisciplinary team involved in the management of patients with CF, and provide strategies for improving the lives of patients. Upon completion of this activity, healthcare providers will be better equipped with imperative information for creating more effective personalized treatment plans and improving patient outcomes.

Register »

Credits: 2.00 AMA PRA Category 1 Credit(s)™
DERM 116x140

Perspectives from the American Academy of Dermatology 2017 Meeting: Clinical Strategies and Scientific Advances in Atopic Dermatitis

Format: Webcast

After many years of little movement in new therapies for patients with atopic dermatitis (AD), significant growth in researching the pathogenesis of AD has resulted in a better understanding of its causes, which has led to new protein targets for novel monoclonal antibodies (mABs). Often diagnosed in infancy, AD can persist into adulthood, affecting 3% to 5% of adults in the United States. Approximately 20% of children and adult patients have been diagnosed with moderate-to-severe AD. For this patient population, these latest advances continue to offer hope, as the current standard of care, which largely centers on symptom management, is suboptimal. This enduring video-based roundtable activity provides the latest updates on AD, including data on emerging and novel treatment options. Expert clinical faculty will also discuss the latest research in AD presented at the 41st Annual Hawaii Dermatology Seminar.  

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910711 116 x 140

Real-world Experience With Neuromuscular Blockade Reversal

Format: Webcast

 Neuromuscular blocking agents (NMBAs) are used in many surgical procedures and have enabled new surgical advances. The expanded landscape of NMB reversal drugs allows for fast and complete neuromuscular blockade (NMB) reversal and the reduction of postoperative complications from residual block. In the United States, neostigmine/ glycopyrrolate and sugammadex are the primary agents for pharmacologic antagonism of NMBAs. While neostigmine and an anticholinergic have been available for decades, sugammadex has only recently become available. We present real-world cases in a variety of surgeries and clinical settings in which the use of NMB reversal agents played a significant role in the patients clinical outcome.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
thumbnail

Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability

Format: Webcast

Effective treatment of major depressive disorder with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and, often, intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. The latest data on multimodal therapies indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and neurotransmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.

Register»

Credits: 3.0 AMA PRA Category 1 Credits™
910720 116 x 140

An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Conference Reporter from AD/PD™ 2017

Format: Conference Reporter

The Alzheimer’s & Parkinson’s Diseases (AD/PD™) 13th International Conference was held in Vienna, Austria, March 29 to April 2, 2017. The conference attracts international medical and scientific professionals worldwide and is at the forefront of unraveling the mechanisms and improving the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910561 125 x 125

REMS Update 2017: Risk Evaluation and Mitigation Strategy

Format: Webcast

This educational supplement has been created to educate healthcare professionals on the safe and proper use of Extended-Release (ER) and Long-Acting (LA) opioids for chronic pain management. Opioids are the cornerstone of modern pain management. They are highly complex molecules which require knowledge and integration of basic science, clinical, pharmacological, psychosocial, abuse, diversion, and public health aspects of opioids. This Opioid Risk Evaluation and Mitigation Strategy (REMS) supplement is a valuable tool that can be utilized daily by everyone in your practice. Continuing Medical Education (CME/CE) credits are available for studying this supplement and completing the online test. The supplement and test can be completed in a little more than three hours, but it will have a lifetime benefit!

Take Course »

Credits: 3.00 AMA PRA Category 1 Credit(s)™ or 3.0 Nursing Contact Hours
910710 116 x 140

ACC 2017: A Therapeutic Update to Reduce Risk and Optimize Outcomes for Patients with Reduced or Preserved Ejection Fraction Heart Failure

Format: Webcast

 

This Official Elsevier Clinical Perspectives and Analysis will cover data presented at the American College of Cardiology 66th Annual Scientific Sessions and Expo held in Washington, DC. The four expert faculty will discuss the most up to date statistics and therapeutic advances for patients with preserved ejection fraction heart failure. The faculty will debate measures of prognosis and biomarkers to enhance treatment plans. Current clinical trial data will be examined in cross reference with new and emerging combination therapies to better serve patients. Upon completion of this activity physicians will gain a better understanding of treatment options to provide better outcomes for patients with ejection fraction heart failure.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
SNO 116x141

New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors

Format: Webcast

The content for this activity is based on the satellite symposium, “New Considerations for the Treatment of Glioblastoma Multiforme: Evaluating the Potential for Immune Checkpoint Inhibitors”, that was presented at the 21st Annual Meeting of the Society for Neuro-Oncology in Scottsdale, Arizona on November 17, 2016. Glioblastoma multiforme (GBM) remains one of the most feared of all malignancies due to its aggressive nature and correspondingly low survival rates. Recently, immunotherapies – particularly immune checkpoint inhibitors – have shown promise in treating patients with GBM in cases where conventional treatment options have failed. This archived symposium activity will provide participants with the opportunity to optimize the diagnosis and management of patients with GBM, including new data and remaining challenges resulting from recent clinical trials in the use of immune checkpoint inhibitors.

Take Course »

Credits: 1.50 AMA PRA Category 1 Credit(s)™
RA 800x275 Combe

Clinical Advances in Rheumatoid Arthritis Resource Center

Format: Resource Center

The Global Learning Center provides you with free access to the latest peer-reviewed clinical information related to the treatment of patients with rheumatoid arthritis (RA). The RA Global Learning Center is a freely accessible platform that aims to increase clinical knowledge by providing continuing medical educational (CME) activities, research articles, and other resources to healthcare providers who treat patients with RA. 

Go to Resource Center »

910643 116 x 140

Clinical Strategies & Scientific Advances in HEPATITIS C VIRUS (HCV)

Format: Medical Meeting Reporter

The treatment of HCV has undergone a dramatic evolution in the last several years. Whereas traditional interferon-based therapy for HCV was limited by poor efficacy and a heavy burden of side effects, interferon-free antiviral regimens are now available, offering new options for patients and altering the approach to this serious disease. The rapid pace of drug research, development, and approval requires frequent updates to treatment guidelines and leaves many clinicians wondering when, in whom, and how to manage chronic HCV infection. 

Take Course »

Credits: 1.25 AMA PRA Category 1 Credit(s)™
910666 116 x 140

Where Are We Now? A Clinicians’ Guide to the Use of Follow-on Insulin for Patients with Diabetes

Format: Webcast

Insulin has been used as a standard treatment for patients with diabetes for almost 100 years.  Over time, advances in insulin development have improved its pharmacologic properties.  Most recently, the US Food and Drug Administration approved a novel, follow-on basal insulin agent, with more expected to be commercially available in the near future. With the imminent availability of follow-on basal insulin agents, clinicians need to be aware of the potential benefits and concerns in order to facilitate informed decision making and to provide the best possible advice and guidance to their patients with diabetes.  This program will review how follow-on insulin products are developed, manufactured, and receive regulatory approval; evaluate clinical trial data for new and emerging follow-on basal insulin agents; and provide practical information and guidance on how they may be incorporated into clinical practice.  While it is unknown how follow-on basal insulins will affect patient outcomes, they have the potential to increase access to treatment among patients with diabetes and reduce healthcare costs.

Take Course »

Credits: 1.25 AMA PRA Category 1 Credit(s)™ or 1.25 Nursing Contact Hours
2016 Alzheimers Disease in Primary Care banner116x140

Alzheimer’s Disease in Primary Care: The Significance of Early Detection, Diagnosis, and Intervention

Format: Webcast

The field of Alzheimer’s disease (AD) is undergoing a profound and rapid change: clinical trials have been redesigned to focus on individuals in the earliest stages of the disease and are including more sensitive measurement tools to better capture changes in cognition and other outcomes. Trial participants undergo PET imaging for amyloid load as a hallmark for dementia, as well as genetic testing to determine likelihood of disease progression and response to therapeutic intervention. Large national and international registries have been established to capture those at risk and to follow their development of cognitive changes longitudinally. Understanding that the disease process starts at least a decade or more before the onset of symptoms has prompted the development of therapeutic interventions acting very early in the disease cascade. For all these reasons, recognizing and diagnosing AD early offers affected individuals and their caregivers the best chance for care planning, access to available symptomatic treatment and community resources, as well as involvement with clinical trials and access to new therapies when they become available. Primary care clinicians play a pivotal role in the early recognition of cognitive impairment in their patients.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
Elsevier CNS 2016 10 Web 140x116

Joining a Conversation on Improving the Multidisciplinary Management of SMA: Now and in the Future

Format: Webcast

The content for this activity is based on the satellite symposium, “Joining a Conversation on Improving the Multidisciplinary Management of SMA: Now and in the Future”, that was presented at the 45th Child Neurology Society Annual Meeting in Vancouver, Canada, on October 27, 2016.

This presentation will provide an overview of the clinical picture of SMA and its natural history, offer guidance on the diagnosis and classification of SMA by neurological examination and gene profiling, discuss the appropriate use of available assessment tools and outcomes measures, and review the emerging treatment landscape via the latest scientific data. Using interactive plenary sessions and selected patient case presentations, our expert panel will encourage the exchange of views and opinions on the rapidly evolving SMA treatment landscape.

Take Course »

Credits: 1.50 AMA PRA Category 1 Credit(s)™
AAPMR 116x140

Spasticity Video Challenge: A Look at Methods for Addressing Difficult Cases

Format: Webcast

This symposium archive will provide participants with the opportunity to assess remaining challenges in the care of patients with spasticity. In addition to reviewing appropriate use of chemodenervation and other treatments, this activity will also highlight techniques for improved communication between physicians and patients regarding the causes of functional impairments, individualized treatment options, customized goals of treatment, and the need for post-intervention rehabilitation and home programs via interactive video case presentations.

The content for this activity is based on the satellite symposium, Spasticity Video Challenge: A Look at Methods for Addressing Difficult Cases, that was presented at the AAPM&R Annual Assembly in New Orleans, Louisiana on October 22, 2016.

Take Course »

Credits: 1.50 AMA PRA Category 1 Credit(s)™
107 116 x 140

Achieving LDL-C Goal for all Patients in the Era of PCSK9 Inhibitors

Format: Webcast

This activity will focus on the most current clinical trial data for achieving LDL-C goal for all patients in the era of PCSK9 inhibitors as presented as an Unofficial Satellite Event at the American Heart Association Scientific Sessions 2016. The expert faculty utilize an interactive panel format to translate evidence-based medicine to optimal clinical decision-making. The educational material of this symposium will provide information that every cardiologists needs to know to improve healthcare outcomes in their patients with cardiovascular disease.

Take Course »

Credits: 2.00 AMA PRA Category 1 Credit(s)™
FH 116 x 140

The Role of PCSK9 Inhibitors in Managing Patients With Familial Hypercholesterolemia

Format: Webcast

This CME activity will focus on the management of patients with familial hypercholesterolemia and the role of PCSK9 inhibitors in this therapeutic area. Expert faculty will review the science of PCSK9, the updated standards of care for the diagnosis, and FH scoring and management of patients with familial hypercholesterolemia. Clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data, will be analyzed. The faculty will guide physicians on how to implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia. Upon completing this activity, physicians will gain knowledge on the most up-to-date care for this cohort of patients.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
910692 116 x 140

ASCO GU 2017: A Therapeutic Update on the Management of Patients with Prostate Cancer

Format: Conference Reporter

Ground-breaking research on the molecular and genetic properties of prostate cancer (PC) was presented at the 2017 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO), held on February 16–18 in Orlando, Florida. This research provided many insights on the genetic changes associated with disease progression and the development of treatment resistance that may help inform treatment decisions for patients with PC in the near future. In this video presentation, three leading experts in the management of PC review key results presented at ASCO-GU 2017 and provide their thoughts on how the results may influence current research and practice.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit(s)™